Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.

Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A; ACCEPT Study Group.

N Engl J Med. 2010 Jan 14;362(2):118-28. doi: 10.1056/NEJMoa0810652.

2.

Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.

Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley LT, Menter A.

Br J Dermatol. 2008 Sep;159(3):704-10. doi: 10.1111/j.1365-2133.2008.08727.x. Epub 2008 Jul 9.

PMID:
18627375
3.

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators.

Lancet. 2008 May 17;371(9625):1675-84. doi: 10.1016/S0140-6736(08)60726-6.

PMID:
18486740
4.

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators.

Lancet. 2008 May 17;371(9625):1665-74. doi: 10.1016/S0140-6736(08)60725-4. Erratum in: Lancet. 2008 May 31;371(9627):1838.

PMID:
18486739
5.

Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.

Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Li S, Dooley LT, Griffiths CE.

Eur J Dermatol. 2007 Sep-Oct;17(5):381-6. Epub 2007 Aug 2.

PMID:
17673380
6.

Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.

van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, Zhou B, Dooley LT, de Vlam K, Geusens P, Birbara C, Halter D, Beutler A.

Arthritis Rheum. 2007 Aug;56(8):2698-707.

7.

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M; CNTO 1275 Psoriasis Study Group.

N Engl J Med. 2007 Feb 8;356(6):580-92.

8.

Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.

Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C; IMPACT 2 Study Group.

Ann Rheum Dis. 2007 Apr;66(4):498-505. Epub 2006 Nov 17.

9.

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB.

J Am Acad Dermatol. 2007 Jan;56(1):31.e1-15. Epub 2006 Sep 6.

PMID:
17097378
10.

Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis.

Kavanaugh A, Antoni C, Mease P, Gladman D, Yan S, Bala M, Zhou B, Dooley LT, Beutler A, Guzzo C, Krueger GG.

J Rheumatol. 2006 Nov;33(11):2254-9. Epub 2006 Sep 1.

PMID:
16960923
11.

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE.

Br J Dermatol. 2006 Jun;154(6):1161-8.

PMID:
16704649
12.

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.

Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE; EXPRESS study investigators.

Lancet. 2005 Oct 15-21;366(9494):1367-74.

PMID:
16226614
13.

Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.

Kavanaugh A, Antoni C, Krueger GG, Yan S, Bala M, Dooley LT, Beutler A, Guzzo C, Gladman D.

Ann Rheum Dis. 2006 Apr;65(4):471-7. Epub 2005 Aug 11.

14.

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.

Br J Dermatol. 2005 May;152(5):954-60.

PMID:
15888152
15.

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.

Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A; IMPACT 2 Trial Investigators.

Ann Rheum Dis. 2005 Aug;64(8):1150-7. Epub 2005 Jan 27.

16.

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.

Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A.

J Am Acad Dermatol. 2004 Oct;51(4):534-42.

PMID:
15389187
17.
18.

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis.

Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG.

J Am Acad Dermatol. 2003 Jun;48(6):829-35.

PMID:
12789171
19.

Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris.

Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U, Dooley LT, Fasanmade AA, Wagner CL.

J Am Acad Dermatol. 2003 Jan;48(1):68-75.

PMID:
12522373
20.

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.

Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB.

Lancet. 2001 Jun 9;357(9271):1842-7.

PMID:
11410193

Supplemental Content

Loading ...
Support Center